Loftus, Edward V. Jr http://orcid.org/0000-0001-7199-6851
Ananthakrishnan, Ashwin N.
Lee, Wan-Ju
Gonzalez, Yuri Sanchez
Fitzgerald, Kristina A
Wallace, Kori
Zhou, Wen
Litcher-Kelly, Leighann
Ollis, Sarah B.
Su, Sylvia
Danese, Silvio
Clinical trials referenced in this document:
Documents that mention this clinical trial
Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
https://doi.org/10.1007/s41669-023-00419-w
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
https://doi.org/10.1080/13543784.2019.1597053
Funding for this research was provided by:
AbbVie
Article History
Accepted: 30 April 2023
First Online: 9 June 2023
Declarations
:
: EVL is acting as the submission's guarantor. AbbVie and Adelphi Values authors collaborated on the conception of the study design, conduct of research, data collection, analysis, and interpretation of data. All authors had access to the data results and participated in the development, review, and approval of this manuscript. No honoraria or payments were made for authorship. All authors have approved the final version of the article, including the authorship list.
: Edward Loftus has received financial support for research from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB; and received consultancy fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Gossamer Bio, Iterative Scopes, Janssen, Morphic, Ono Pharma, Pfizer, Protagonist, Scipher Medicine, Sun Pharma, Surrozen, Takeda, and UCB. Ashwin Ananthakrishnan has received funding from the US National Institutes of Health, served on scientific advisory boards for Gilead and received research funding from Pfizer. Wan-Ju Lee, Yuri Sanchez Gonzalez, Kristina Fitzgerald, Kori Wallace, and Wen Zhou are full-time employees of AbbVie and may hold AbbVie stock and/or stock options. Leighann Litcher-Kelly, Sarah Ollis, and Sylvia Su are employed by Adelphi Values LLC, which received payment from AbbVie Inc. to support the research activities presented in this publication. Silvio Danese has received consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer, Roche, Sandoz, Takeda, TiGenix, UCB, and Vifor Pharma. No honoraria or payments were made for authorship.
: This work was supported by AbbVie, Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. Writing support was provided by Naomi Suminski and Emma Pranschke of Adelphi Values and funded by AbbVie, Inc.
: The data that support the findings of this research may be available from AbbVie, but restrictions apply to the availability of these data, which were used under license for the current research, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of AbbVie.
: Ethical approval for the interview study was obtained via a centralized independent review board. Ethical approval for the clinical trials was obtained separately.
: All interview and clinical trial participants provided consent (or assent with parental/guardian consent, as appropriate).
: Not applicable.
: May be available upon reasonable request.